Protein-Protein Interactions In Drug Discovery V56

Researchers in pharmacy, medical information, and other biological and medical specialties explore how therapeutic strategies are now targeting interactions between proteins, rather than just small molecules. Among the topics are predicting protein-protein interactions between and within species to facilitate systems biology studies, the importance of three-dimensionality for modulators of protein-protein interactions, interactive technologies for leveraging the known chemistry of anchor residues to disrupt protein interactions, inhibiting LFA-1//ICAM interaction to treat autoimmune disease, potent and selective orally available oxytocin antagonists restosiban and epelsiban, and peptidic inhibitors of protein-protein interactions for cell adhesion receptors. Annotation c2013 Book News, Inc., Portland, OR (booknews.com)

Alexander D?mling studied Chemistry and Biology at the Technical University Munich, Germany. After obtaining his PhD under the supervision of Ivar Ugi, he spent a postdoctoral year at the Scripps Research Institute in La Jolla (USA) in the group of Nobel Laureate Barry Sharpless. In 2004 he performed his habilitation at the Technical University of Munich. Since 2006 he is associate professor at the University of Pittsburgh in the Department of Pharmacy with secondary appointments in Chemistry and Computational Biology. Dr. D?mling is founder of several biotech companies, including Morphochem and R&D Biopharmaceuticals. His research centers around the discovery of antagonists of protein-protein interactions in the therapeutic areas of oncology, infectious and neglected tropical diseases.